Everest Medicines Limited (1952.HK)

HKD 50.8

(3.15%)

Total Liabilities Summary of Everest Medicines Limited

Everest Medicines Limited's latest annual total liabilities in 2023 was 804.1 Million CNY , down -16.26% from previous year.
Everest Medicines Limited's latest quarterly total liabilities in 2024 Q1 was -4.96 Billion CNY , down -717.91% from previous quarter.
Everest Medicines Limited reported annual total liabilities of 960.25 Million CNY in 2022, up 27.38% from previous year.
Everest Medicines Limited reported annual total liabilities of 753.82 Million CNY in 2021, up 18.51% from previous year.
Everest Medicines Limited reported quarterly total liabilities of 804.1 Million CNY for 2023 Q3, up 68.44% from previous quarter.
Everest Medicines Limited reported quarterly total liabilities of 804.1 Million CNY for 2023 FY, down -16.26% from previous quarter.

Annual Total Liabilities Chart of Everest Medicines Limited (2023 - 2018)

Historical Annual Total Liabilities of Everest Medicines Limited (2023 - 2018)

Year	Total Liabilities	Total Liabilities Growth
2023	804.1 Million CNY	-16.26%
2022	960.25 Million CNY	27.38%
2021	753.82 Million CNY	18.51%
2020	636.11 Million CNY	-78.78%
2019	2.99 Billion CNY	79.44%
2018	1.67 Billion CNY	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	-4.96 Billion CNY	-717.91%
2023 Q3	804.1 Million CNY	68.44%
2023 FY	804.1 Million CNY	-16.26%
2023 Q4	804.1 Million CNY	0.0%
2023 Q2	477.37 Million CNY	0.0%
2023 Q1	477.37 Million CNY	-50.29%
2022 Q4	960.25 Million CNY	0.0%
2022 Q3	960.25 Million CNY	-0.34%
2022 Q2	963.54 Million CNY	0.0%
2022 Q1	963.54 Million CNY	27.82%
2022 FY	960.25 Million CNY	27.38%
2021 Q3	753.82 Million CNY	32.85%
2021 Q2	567.42 Million CNY	0.0%
2021 Q1	567.42 Million CNY	-10.8%
2021 FY	753.82 Million CNY	18.51%
2021 Q4	753.82 Million CNY	0.0%
2020 Q4	636.11 Million CNY	0.0%
2020 Q1	2.7 Billion CNY	0.0%
2020 Q3	636.11 Million CNY	0.0%
2020 Q2	- CNY	-100.0%
2020 FY	636.11 Million CNY	-78.78%
2019 FY	2.99 Billion CNY	79.44%
2019 Q1	- CNY	0.0%
2018 FY	1.67 Billion CNY	0.0%

Peer Total Liabilities Comparison of Everest Medicines Limited

Name	Total Liabilities	Total Liabilities Difference
Uni-Bio Science Group Limited	152.81 Million HKD	-426.184%
CK Life Sciences Int'l., (Holdings) Inc.	7.05 Billion HKD	88.607%